Cost-effectiveness of a shared computerized decision support system for diabetes linked to electronic medical records

Journal of the American Medical Informatics Association

Volumn 19, Issue 3, 2012, Pages 341-345

  O'Reilly, Daria ^a,b   Holbrook, Anne ^b,c   Blackhouse, Gordon ^a,b   Troyan, Sue ^b,c   Goeree, Ron ^a,b  

^a Healthcare Hamilton   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c CENTRE FOR EVALUATION OF MEDICINES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

ADULT; AMPUTATION; ARTICLE; BLINDNESS; BODY MASS; COMPUTERIZED DECISION SUPPORT SYSTEM; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION SUPPORT SYSTEM; ELECTRONIC MEDICAL RECORD; EVIDENCE BASED MEDICINE; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; STROKE; SYSTOLIC BLOOD PRESSURE;

COST-BENEFIT ANALYSIS; DECISION SUPPORT SYSTEMS, CLINICAL; DIABETES MELLITUS, TYPE 2; ELECTRONIC HEALTH RECORDS; FEMALE; HEALTH CARE COSTS; HEALTH RECORDS, PERSONAL; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; ONTARIO; PRIMARY HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMINDER SYSTEMS;

EID: 84862628494     PISSN: 10675027     EISSN: 1527974X     Source Type: Journal    
DOI: 10.1136/amiajnl-2011-000371     Document Type: Article

References (20)

1. Public Health Agency of Canada. Diabetes in Canada: National Statistics and Opportunities for Improved Surveillance, Prevention, and Control. 1999. http://www.phac-aspc.gc.ca/publicat/dic-dac99/d07_e.html (accessed 1 Apr 2008).
2. Canadian Diabetes Association. The Burden of Diabetes in Ontario. 2009. http://www.diabetes.ca/documents/about-diabetes/ODCM.pdf
3. Canadian Diabetes Association. An Economic Tsunami: the Cost of Diabetes in Canada. 2009. http://www.diabetes.ca/documents/get-involved/FINAL_Economic_Report.pdf
4. American Diabetes Association. Standards of medical care in diabetese2008. Diabetes Care 2008;31(Suppl 1):S12-54.
5. Meltzer S, Leiter L, Daneman D, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. CMAJ 1998;159(Suppl 8):S1-29.
6. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735-44.
7. O'Reilly D, Hopkins R, Blackhouse G, et al. Long-term cost-utility analysis of a multidisciplinary primary care diabetes management program in Ontario. Can J Diabetes 2007;31:205-14.
8. Garg AX, Adhikari NK, McDonald H, et al. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. JAMA 2005;293:1223-38.
9. Ofman JJ, Badamgarav E, Henning JM, et al. Does disease management improve clinical and economic outcomes in patients with chronic diseases? A systematic review. Am J Med 2004;117:182-92.
10. Bagust A, Hopkinson PK, Maier W, et al. An economic model of the long-term health care burden of type II diabetes. Diabetologia 2001;44:2140-55.
11. Caro JJ, Klittich WS, Raggio G, et al. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes. Clin Ther 2000;22:116-27.
12. Clarke PM, Gray AM, Briggs A, et al; UK Prospective Diabetes Study (UKDPS) Group. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59.
13. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl 1): S5-26.
14. Tilden DP, Mariz S, O'Bryan-Tear G, et al. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics 2007;25:39-54.
15. Anon. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ 1998;317:720-6.
16. Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ 2000;320:1373-8.
17. Holbrook A, Thabane L, Keshavjee K, et al. Individualized electronic decision support and reminders to improve diabetes care in the community: COMPETE II randomized trial. CMAJ 2009;181:37-44.
18. Medical Advisory Secretariat. Bariatric Surgery for People with Diabetes and Morbid Obesity: an evidence-based analysis. Ontario Health Technology Assessment Series 2009;9(22).
19. Medical Advisory Secretariat. Continuous subcutaneous insulin infusion pumps for type 1 and type 2 adult diabetic populations: an evidence-based analysis. Ontario Health Technology Assessment Series 2009;9(20).
20. Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press, 2006.